Cerus

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cerus excels in Q4 with record growth and strategic milestones

Cerus delivered a strong performance in Q4 2022, driven by the success of the INTERCEPT Blood System and robust product revenue growth.
While facing challenges in inventory management and international expansion, the company's focus on innovation and upcoming milestones position it for future growth.
Opportunities in regulatory submissions, market expansion, and achieving cash flow breakeven in 2023 underscore Cerus' potential for sustained success and market leadership.

Cerus reports Q1 revenue dip, eyes China growth opportunities

Cerus navigated Q1 with a focus on financial stability, product adoption, and global market expansion. Despite revenue challenges, the company's strategic initiatives and successful debt refinancing position it for future growth. Addressing inventory management, label expansion, and market-specific hurdles will be key to unlocking opportunities.

Cerus (CERS) reports robust Q2 performance amidst growth challenges

Cerus delivered a strong performance in Q2, marked by revenue growth, improved margins, and effective cost management.
While facing challenges in U.S. customer ordering patterns and market penetration, the company remains well-positioned for growth.
With a focus on operational efficiency, product development, and market expansion, Cerus is poised to capitalize on growth opportunities.
The company's financial strength, coupled with strategic initiatives, sets a positive trajectory for continued progress and success.

Cerus reports robust Q3 sales, adjusts revenue guidance for 2023

Cerus shows strong sales growth, positive market sentiment, and progress in key trials. Challenges include revenue guidance adjustment due to delayed sales agreement. Opportunities lie in expanding product demand and achieving EBITDA breakeven.

Cerus surpasses 16 million kits sold, expects double-digit growth

Cerus delivered a strong performance in Q4 2023, surpassing 16 million kits sold and achieving positive non-GAAP adjusted EBITDA for the first time.
The company's focus on the platelet franchise and IFC business yielded growth, setting the stage for continued expansion in 2024.
While facing challenges in revenue expectations and market competition, Cerus remains well-positioned to capitalize on growth opportunities.
Guidance for 2024 indicates a positive outlook with expectations of sustained growth in the INTERCEPT platelet business and IFC revenue.

Cerus reports robust Q1 earnings, eyes international growth opportunities

Cerus' Q1 2024 earnings call highlighted strong financial performance, positive trial results, and reiterated revenue guidance. The company is focused on achieving breakeven non-GAAP adjusted EBITDA for the year. Challenges include regulatory progress and working capital adjustments, while opportunities exist in international market expansion and operational optimization.

Cerus excels in Q2 2024, raises revenue guidance amid global expansion

Cerus demonstrates strong financial performance, driven by global adoption of INTERCEPT. Focus on expanding sales in key markets and addressing analyst queries to sustain growth momentum. Future growth prospects look promising with a commitment to transparency and investor engagement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cerus Corporation (NASDAQ:CERS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Matt Notarianni – Senior Director-Investor Relations Obi Greenman – President and Chief Executive Officer Vivek Jayaraman – Chief Operating Officer Kevin Green – Chief Financial Officer Conference Call Participants Brandon Folkes – Cantor Fitzgerald Eric Anderson – Cowen Operator Good day, ladies and gentlemen. Thank you for standing by.

Cerus Corporation (CERS) CEO Obi Greenman on Q1 2022 Results - Earnings Call Transcript

Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2022. Recent developments and highlights include: First quarter 2022 total revenue of $43.0 million, reflecting a 46% increase over the prior year period. Total revenue was composed of (in thousands, except %):   Three Months Ended     March 31,     2022 2021 Change Product revenue $ 37,444 $ 23,379 60 % Government contract revenue   5,576   6,187 (10 %) Tot

Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. This new contract replaces the current one with Fresenius Kabi that was set to expire in July 2025. “Our long-standing partnership with Fresenius Kabi has enabled us to ramp the adoption of our pathogen inactivation technology broadly around the globe, as we work to fulfill our mission of making the INTE

Cerus Corporation Announces New Manufacturing and Supply Agreement With Fresenius Kabi For INTERCEPT Blood System Sets

Archer Aviation

Atai Life Sciences BV

Compugen

Ginkgo Bioworks Holdings

Joby Aviation

Nano Dimension

Invitae

Quantum-Si

Zymergen

Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets. Under the terms of this contract, Cerus will continue to supply the Red Cross the INTERCEPT Blood System used to produce pathogen reduced platelets, in support of the Red Cross goal to transition toward a full pathogen reduced platelet supply for its hospital customers across the U.S. “The Red Cross i

Cerus Corporation Announces Multi-Year Contract for the INTERCEPT Blood System for Platelets with the American Red Cross

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Inv

Cerus Corporation to Release First Quarter 2022 Financial Results on May 5, 2022

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus' chief financial officer, is scheduled to participate at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 1:30 p.m. EST. A live webcast of the event will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event. ABOUT CERUS Cerus Co

Cerus Corporation to Participate at the Cowen 42nd Annual Health Care Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Cerus (CERS) Have the Potential to Rally 90% as Wall Street Analysts Expect?

Cerus Corporation (CERS) CEO Obi Greenman on Q4 2021 Results - Earnings Call Transcript

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2021. Recent developments and highlights include: Fourth quarter 2021 total revenue of $50.1 million, reflecting a 49% increase over the prior year period. For the full year, 2021 total revenue was $159.5 million, reflecting a 40% increase over the prior year period. Total revenue was composed of (in thousands, except %):     Three Months E

Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides,

Cerus Corporation to Release Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference. On Wednesday, February 16th at 9:00 a.m. EST, Vivek Jayaraman, Cerus' chief operating officer, is scheduled to participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference. BTIG-hosted

Cerus Corporation to Participate in Upcoming Virtual Investor Conferences

Cerus provided 2022 product revenues guidance of a record $157 to $164 million, after delivery of better than expected 2021 product revenues of $130.9 Million (42% higher than 2020 product revenues). U.S.blood centers increased purchases of Cerus' INTERCEPT platelet kits to comply with FDA order effective Oct.1.

Cerus Corporation: Outperforming And Gaining Momentum

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2021, provided product revenue guidance for 2022 and provided an update on its INTERCEPT Blood System for Cryoprecipitation offering, which is used to produce INTERCEPT Fibrinogen Complex. Cerus' unaudited preliminary product revenue for the fourth quarter of 2021 totaled $39.9 million, representing an increase of 41% over the $28.2 million recogniz

Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update

Arcos Dorados Hlds

ARKO

Nissan Motor Co Ltd

Growth stocks tend to perform well when the economy starts to pick up. Nissan Motor (NSANY), Arko Corp. (ARKO), Arcos Dorados (ARCO) and Cerus (CERS) look well-poised to grow.

4 Growth Stocks Under $10 to Buy for 2022

The consensus price target hints at a 43.9% upside potential for Cerus (CERS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Cerus (CERS)? Wall Street Analysts Think 44%

NextGen Healthcare Inc

QuidelOrtho Corp

Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.

3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Cerus (CERS) Could Surge 35%: Read This Before Placing a Bet

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus' chief financial officer, is scheduled to participate in the Stephens Annual Investment Conference in Nashville, Tenn., on Friday, December 3, 2021 at 2:00 p.m. ET. A live webcast of the event will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event. ABO

Cerus Corporation to Participate in Stephens Annual Investment Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial officer, are scheduled to participate in the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 4:40 p.m. ET. A live webcast of the events will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approx

Cerus Corporation to Participate in Stifel 2021 Virtual Healthcare Conference

Cerus Corporation (CERS) CEO Obi Greenman on Q3 2021 Results - Earnings Call Transcript

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2021. Recent developments and highlights include: Third quarter 2021 total revenue of $42.1 million, reflecting a 44% increase over the prior year period. Total revenue was composed of (in thousands, except %):   Three Months Ended         Nine Months Ended         September 30,         September 30,         2021   2020   Change     2021   2020   Change

Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full-Year Product Revenue Guidance

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the

News for Cerus Stock (CERS)